Menu
Search
|

Menu

Close
X

Therapix Biosciences Ltd TRPX.OQ (NASDAQ Stock Exchange Capital Market)

5.45 USD
-0.01 (-0.18%)
As of Feb 16
chart
Previous Close 5.46
Open 5.46
Volume 541
3m Avg Volume 8,120
Today’s High 5.48
Today’s Low 5.34
52 Week High 10.90
52 Week Low 4.42
Shares Outstanding (mil) 138.36
Market Capitalization (mil) 67.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.076
FY16
-0.051
FY15
-0.109
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
9.14
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-210.69
14.43
Return on Equity (TTM)
vs sector
-209.27
16.13

EXECUTIVE LEADERSHIP

Ascher Shmulewitz
Chairman of the Board, Interim Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Guy Goldin
Vice President - Finance, Since 2016
Salary: --
Bonus: --
Doron Ben Ami
Vice President-Strategy, Since 2015
Salary: --
Bonus: --
Adi Zuloff-Shani
Vice President-Technologies, Since 2016
Salary: --
Bonus: --
Ahmed Alimi
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4 Ariel Sharon Street
Hashahar Tower, 16th Floor
GIV'ATAYIM     5320047

Phone: +9723.6167055
Site:

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine, based on surface proteins that are highly conserved among pneumococcal strains, hence able to stimulate protective immune responses against pneumococcal strains in general; Alzheimer’s Disease Immunotherapy develops immunotherapeutic products for Alzheimer’s disease; and Adjuvant-Delivery platform, VaxiSome, serves both as a potent adjuvant for stimulating enhanced immune responses via the Th1 and Th2 pathways as well as an efficient delivery system. This liposomal adjuvant delivery system also may be applied to augment the bioactivity of other established adjuvants and cytokines.

SPONSORED STORIES